# LABORATORY STANDARDS AND PROCEDURES WORKGROUP

April 24, 2019

Co-chairs: Kellie Kelm, PhD & Susan Tanksley, PhD

	TOPIC	PRESENTER	
genda	Welcome and Roll Call (5 min)	Kellie Kelm Susan Tanksley	
	Welcome New Members (8 min)		
	Nathalie Lepage, PhD, FCCMG, FCACB Laboratory Head, Inherited Metabolic Diseases, Newborn Screening Ontario		
	Miriam Schachter, PhD Research Scientist, Newborn Screening Laboratory, New Jersey Department of Health	Kellie Kelm Susan Tanksley	
	Stan Berberich, PhD (returning) Program Manager, Medical Screening, State Hygienic Laboratory at The University of Iowa		
	George Dizikes, PhD, HCLD/CC(ABB) (returning) Director, Knoxville Regional Laboratory, Division of Laboratory Services		
	New conditions implementation update (12 min)	APHL	
	Lessons from the Field: SMA Screening New England (10 min) Utah (10 min) Discussion (10 min)	Anne Comeau Andy Rohrwasser All	
	Debrief and Discussion: RUSP Condition Nomination & Evidence Review Process (30 min)	All	
	Wrap-up/Next Steps (5 min)	Kellie, Susan	

A

## **Workgroup Roster**

Mei Baker Carla Cuthbert Tricia Hall Scott McCandless Scott Shone Holly Winslow Stan Berberich<sup>#</sup> George Dizikes<sup>#</sup> Travis Henry Jelili Ojodu Bonnie Taffe Michele Caggana Rosemary Hage Nathalie Lepage\* Miriam Schachter\* Michael Watson

- Chair: Kellie Kelm
- Co-chair: Susan Tanksley
- HRSA staff: Kathryn McLaughlin

# Workgroup Charge

Define and implement a mechanism for the periodic review and assessment of

- 1. The conditions included in the uniform panel
- 2. Laboratory procedures utilized for effective and efficient testing of the conditions included in the uniform panel.
- 3. Infrastructure and services needed for effective and efficient screening of the conditions included in the uniform panel

# Project 1

- Laboratory procedures: Explore the role of next generation sequencing in newborn screening
  - Screening is currently based on phenotypic data. How do we accumulate the data to identify correlation between phenotypic & genotypic data?
  - Are there conditions for which sequencing is the only screening method?
  - What do you gain/lose from NGS?
  - Which data do you report?
    - What do you do with variants of unknown significance?
    - When do you report carrier status? Are there particular conditions where reporting carrier status is important?
  - What new infrastructure needs to be built for NGS?

## Project 2

• Infrastructure and services: A portion of the timeliness initiatives fits here:

- Review data related to testing (Timeliness 1.0)
- What are the implications of earlier specimen collection (<24 hrs)?
- What are the unforeseen consequences and costs of timeliness?

# **Project 3**

- Impact of broad phenotypes on laboratories
  - Share lessons learned on identifying late onset Pompe disease, SMA cases with 2, 3, or 4 copies of SMN2, etc.
  - Use information to refine the target of the RUSP condition?

### **APHL New Conditions Implementation Update**

- Funded 16 states for implementation projects and 3 states as Peer Network Resource Centers (PNRCs)
- PNRCs are early adopters of the 3 conditions (Pompe, MPS1, X-ALD) that would help the other states with either MS or digital microfluidics
- New conditions workgroup starting soon, George Dizikes and Amy Gaviglio, co-chairs
  - Webinars
  - Technical assistance
- Additional funding has been received for SMA and other disorders as they get added for the next 5 years



Newborn Screening for Spinal Muscular Atrophy Massachusetts' experience

### ACHDNC Laboratory Working Group April 23, 2019 Anne Marie Comeau, Ph.D

Deputy Director, New England Newborn Screening Program Professor of Pediatrics, UMass Medical School



### Assay Development for SMA NBS

Two factors key to development:


- SMA is related to the absence of a fully functional gene that produces a Survival of Motor Neuron (SMN) protein, *SMN1*
- 95% SMA patients show homozygous loss of *SMN1* exon 7

### Assay is designed to detect HOMOZYGOUS ABSENCE OF SMN1 EXON 7.


It is not designed to detect carriers.



#### Massachusetts' SMA NBS Laboratory Testing Algorithm




### Number of Babies Screened for SMA



#### 69,169 as of April 16



# Infants with a specimen prompting Tier 2 n = 90





# SMA screening in Utah: One year update

Andy Rohrwasser arohrwasser@utah.gov






# SMA/TREC Assay Method

- PCR-Based Triplex Assay: modified CDC protocol
  - SMN1 Deletion of exon 7 of SMN1 gene (SMA)
  - TREC T-cell receptor excision circles (SCID)
  - RPP30 Internal control


### • Automated Extraction Tecan Evo 200

- 2 step washing protocol
  - PBS/Tween 20 (room temperature)
  - Qiagen Solution 2 (room temperature)
- Qiagen Solution 2 (70C) elution
- 96 well to 384 well transition
- Real-Time PCR
  - Roche LightCycler 480 II
  - 384 well format

### SMA Screening and Diagnostic Workflow




### SCID Screening and Diagnostic Workflow



Case	Age at NBS report	Age at clinic evaluation	Age at confirmatory testing result	Confirmatory Result	Treatment type
Case 1	6 days	7 days	13 days	SMN1 = 0 SMN2 = 3	Gene therapy trial
Case 2	7 days	8 days	14 days	SMN1 = 0 SMN2 = 3	Gene therapy trial

## **Statistics**



SMA: you have the deletion or you don't/binary


TREC as a SCID marker: continuous or quantitative trait phenotype

## Problem: 2 false positive SCID cases

- 2 cases abnormal on 1<sup>st</sup> NBS; referred for flow cytometry; results normal/not consistent with SCID
  - Retested SCID cases using EnLite TREC: Normal/low TREC levels

• Hypothesis: differential binding/elution kinetics TREC/gDNA





### Debrief and discussion:

### **RUSP Condition Nomination & Evidence Review Process**

- •Need to define the terminology for the evidence review process (e.g. what is a case definition)
- Set the case definition for the condition under consideration it's what the laboratory is supposed to find
- Is identifying carriers a benefit or a harm?
- Very difficult to find published evidence of harm (doesn't mean we shouldn't look for it)
- Need better assessment of the availability of the confirmatory test and turnaround time, specialty care availability
- Systematic way to measure family experiences e.g. Maslow's hierarchy of needs